ORLANDO, Fla. — With dosing underway in a pivotal phase 3 trial, Star Therapeutics is illuminating the clinical potential of its anti-bleeding antibody VGA039. In a phase 1/2 trial in von Willebrand disease (VWD), the molecule substantially reduced bleeding in eight patients. “We're seeing significant reductions in bleeds across all types of VWD and all types of bleeds,” Star founder...